Roche Court Win Keeps Sandoz' Biosimilar Rituximab Off Australian Market For A Year

A decision by an Australian court to prevent Sandoz from launching its biosimilar rituximab in Australia until August 2019 means a continued monopoly for Roche and lost sales for Sandoz, while the healthcare system misses out on significant potential savings.